Royalty Pharma, plc (RPRX) Rallied on Earnings Beat

2 days ago 3

Soumya Eswaran

Mon, June 29, 2026 astatine 8:16 AM CDT 3 min read

Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 capitalist missive for "Meridian Hedged Equity Fund". A transcript of the missive tin beryllium downloaded here. The Fund invests successful high-quality maturation companies and mitigates hazard by penning telephone options. Following the late-February onslaught connected Iran, lipid prices surged, starring to a risk-off sentiment, boosting vigor assemblage performance. Large-cap exertion stocks declined arsenic investors rotated towards smaller companies and much antiaircraft worth investments. Market conditions are becoming challenging owed to reduced expectations for a Federal Reserve complaint chopped and expanding geopolitical uncertainty. The Fund returned 0.08% (net) for the quarter, outperforming the S&P 500 Index, which fell 4.33%, and the CBOE S&P 500 BuyWrite Index, which declined 0.92%. At the extremity of the period, 43% of the portfolio was unhedged, portion the remainder was invested successful companies with covered telephone options. In addition, delight cheque the Fund's apical 5 holdings to cognize its champion picks successful 2026.

In its first-quarter 2026 capitalist letter, Meridian Hedged Equity Fund highlighted Royalty Pharma plc (NASDAQ:RPRX). Royalty Pharma plc (NASDAQ:RPRX) is simply a biopharmaceutical concern institution that specializes successful acquiring royalty interests and backing innovation successful the biopharmaceutical industry. On June 26, 2026, Royalty Pharma plc (NASDAQ:RPRX) closed astatine $56.23 per share, reflecting a marketplace capitalization of $32.38 billion. Royalty Pharma plc (NASDAQ:RPRX) posted a one-month instrumentality of 1.90%, and its shares gained 56.06% implicit the past 52 weeks.

Meridian Hedged Equity Fund stated the pursuing regarding Royalty Pharma plc (NASDAQ:RPRX) successful its Q1 2026 capitalist letter:

"Royalty Pharma plc (NASDAQ:RPRX) is the industry's largest purchaser of biopharmaceutical royalties, partnering with innovators to co money late-stage objective trials and acquiring existing royalties connected approved therapies. Our concern thesis focuses connected the company's quality to present diversified, long-duration currency flows tied to blockbuster drugs portion avoiding the research, development, and manufacturing risks emblematic of accepted biotech firms. Its standard and structural advantages enactment the imaginable for dependable top-line maturation that is comparatively insulated from broader macroeconomic volatility. The banal performed good successful the 4th pursuing different net bushed and expectations for continued spot from established franchises. We maintained our presumption passim the quarter."

Read Entire Article